Licensing status

Publication and contact information


Liver cancer


In vitro and mouse studies suggest hepatocellular carcinoma (HCC) with amplifications in VEGF-A may be particularly susceptible to Nexavar sorafenib. In mice with HCC and in human tumor samples, VEGF-A was amplified in a subset of tumors. In a mouse model of HCC, Nexavar induced an antitumor response specifically in the Vegf-a-amplified tumor subset. In a retrospective analysis of patients with HCC treated with Nexavar, survival was improved in those with VEGF-A amplifications. Next steps include validation in an additional cohort.
Nexavar sorafenib, which targets VEGF receptor (VEGFR) and other kinases, is marketed by Amgen Inc. and Bayer AG to treat various cancers.

SciBX 7(18); doi:10.1038/scibx.2014.522
Published online May 8, 2014

Patent application filed; licensing negotiations under way with an undisclosed biotech in Israel

Horwitz, E. et al. Cancer Discov.; published online March 31, 2014;
Contact: Eli Pikarsky, The Hebrew University Hadassah Medical School, Jerusalem, Israel